To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00482196
Recruitment Status : Completed
First Posted : June 5, 2007
Last Update Posted : April 28, 2015
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
To study different doses of MK0493 for safety, efficacy and tolerability in obese patients.

Condition or disease Intervention/treatment Phase
Obesity Drug: MK0493 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 173 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : July 2005
Actual Primary Completion Date : March 2006
Actual Study Completion Date : March 2006

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient is between 21 and 65 years of age

Exclusion Criteria:

  • HIV positive as determined by medical history
  • Patient is pregnant, lactating or plans to become pregnant
  • Patient has undergone surgical treatment for obesity
  • Patient has undergone a surgical procedure within 4 weeks prior to Visit 1 or plans to undergo a surgical procedure during the study
  • Patient plans to consume more than 2 glasses of grapefruit juice per day during the study
  • Patient has participated in another clinical study (involving an investigational drug) within 3 months prior to restudy screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00482196

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.